



# PEDIATRIC: Actemra Order Form

(tocilizumab) See separate adult form

FAX TO: 972.499.9210

## PATIENT INFORMATION

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_ Sex: M F Ht: \_\_\_\_\_ Wt: \_\_\_\_\_ lbs kg  
Primary Language: \_\_\_\_\_ Allergies: \_\_\_\_\_  
Patient Preferred Location: \_\_\_\_\_

<ICD 10 CODE REQUIRED>

## DIAGNOSIS & CLINICAL INFORMATION

### ICD 10 Code (PROVIDE COMPLETE CODE)

M08.2 \_\_\_\_\_ Juvenile Rheumatoid Arthritis w/Systemic Onset  
M08.3 Juvenile Rheumatoid Polyarthritis (Seronegative)  
Other: \_\_\_\_\_

**REQUIRED:** Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy.

**LAB RESULTS:** Negative TB within 12 months. CBC with diff, Platelets, AST, ALT, and Lipid panel within 60 days.

## PRESCRIPTION

### ACTEMRA (tocilizumab)

Weight < 30 kg infuse in 50 mL of 0.9% Sodium Chloride  
Weight ≥ 30 kg infuse in 100 mL of 0.9% Sodium Chloride

#### Cytokine Release Syndrome

Every 2 weeks (no < 14 days) for one year

IV: (wt < 30 kg): Infuse 12 mg/kg

IV: (wt ≥ 30 kg): Infuse 8 mg/kg

#### Polyarticular Juvenile Idiopathic Arthritis

Every 4 weeks (no < 28 days) for one year

IV: (wt < 30 kg): Infuse 10 mg/kg

IV: (wt ≥ 30 kg): Infuse 8 mg/kg

#### Systemic Juvenile Idiopathic Arthritis

Every 2 weeks (no < 14 days) for one year

IV: (wt < 30 kg): Infuse 12 mg/kg

IV: (wt ≥ 30 kg): Infuse 8 mg/kg

### Lab Orders+

Required: Negative TB

CBC with diff, Platelets, AST, and ALT, at 2nd infusion, then every 8 weeks for Polyarticular JIA and every 4 weeks for Systemic JIA.  
Lipid Panel, at 2nd infusion, then every six months

**+ Medix Infusion will draw maintenance labs unless otherwise directed by Referring Provider**

Patient Weight: \_\_\_\_\_ lbs or \_\_\_\_\_ kg

Is the patient on any other disease modifying therapy? Yes No  
If yes, please note therapy and last dose: \_\_\_\_\_

**Post Treatment Observations:** The patient is observed for 30 minutes following the first administration.

**Adverse Events:** In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol.

**Comments:**

\_\_\_\_\_  
\_\_\_\_\_

## PRESCRIBER INFORMATION

Prescriber Name: \_\_\_\_\_ Signature: \_\_\_\_\_

Date: \_\_\_\_\_ NPI #: \_\_\_\_\_ Specialty: \_\_\_\_\_

Supervising Physician: \_\_\_\_\_ (If Applicable)

Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Contact Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Email: \_\_\_\_\_